Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MIRATI THERAPEUTICS, INC.

(MRTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
172.42(c) 177.87(c) 171.94(c) 175.26(c) 178.28(c) Last
290 498 715 882 358 320 248 592 282 836 Volume
+2.49% +3.16% -3.33% +1.93% +1.72% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 17,6 M - -
Net income 2021 -609 M - -
Net cash position 2021 769 M - -
P/E ratio 2021 -15,0x
Yield 2021 -
Sales 2022 67,5 M - -
Net income 2022 -664 M - -
Net cash position 2022 516 M - -
P/E ratio 2022 -14,1x
Yield 2022 -
Capitalization 9 203 M 9 203 M -
EV / Sales 2021 479x
EV / Sales 2022 129x
Nbr of Employees -
Free-Float 92,4%
More Financials
Company
Mirati Therapeutics, Inc. is a clinical-stage oncology company. The Company is focused on developing therapeutics to address the genetic and immunological promoters of cancer. The Company's clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an investigational, highly selective and potent, oral small-molecule therapy designed to shrink... 
More about the company
Ratings of Mirati Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about MIRATI THERAPEUTICS, INC.
10/07MIRATI THERAPEUTICS : to Partner With Sanofi on Adagrasib-SAR442720 Combo Lung Cancer Tria..
MT
10/07MIRATI THERAPEUTICS : to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination..
PR
10/04MIRATI THERAPEUTICS : to Present New Research From its Innovative Oncology Pipeline at the..
PR
09/24MIRATI THERAPEUTICS : Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
PR
09/23MIRATI THERAPEUTICS : Stifel Starts Mirati Therapeutics at Buy With $202 Price Target
MT
09/21MIRATI THERAPEUTICS : Jefferies & Co Adjusts Mirati Therapeutics PT to $219 From $193, Mai..
MT
09/21MIRATI THERAPEUTICS : Oppenheimer Adjusts Mirati Therapeutics PT to $175 From $160, Mainta..
MT
09/21MIRATI THERAPEUTICS : SVB Leerink Adjusts Mirati Therapeutics' Price Target to $205 from $..
MT
09/21MIRATI THERAPEUTICS : Morgan Stanley Adjusts Mirati Therapeutics PT to $173 From $160, Mai..
MT
09/20MIRATI THERAPEUTICS : Reports Results From Phase 2 Study of MRTX-500
MT
09/20MIRATI THERAPEUTICS : Names David Meek as CEO
MT
09/20MIRATI THERAPEUTICS : Charles M. Baum, M.D., Ph.D to Continue in New Role of President, Fo..
PU
09/20MIRATI THERAPEUTICS : Announces Long-term Survival Results from an Exploratory Analysis of..
PR
09/20Mirati Therapeutics, Inc. announces results from a post hoc exploratory analysis of the..
CI
09/20MIRATI THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Finan..
AQ
More news
News in other languages on MIRATI THERAPEUTICS, INC.
09/20Mirati Therapeutics annonce les résultats de l'étude de phase 2 sur MRTX-500
01/04Quels ETF choisir pour investir dans les valeurs moyennes ?
2020Un fármaco de Amgen reduce tumores en pacientes con cáncer de pulmón con mutación de ge..
More news
Analyst Recommendations on MIRATI THERAPEUTICS, INC.
More recommendations
Chart MIRATI THERAPEUTICS, INC.
Duration : Period :
Mirati Therapeutics, Inc. Technical Analysis Chart | MRTX | US60468T1051 | MarketScreener
Technical analysis trends MIRATI THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 178,28 $
Average target price 215,64 $
Spread / Average Target 21,0%
EPS Revisions
Managers and Directors
David D. Meek Chief Executive Officer & Director
Charles M. Baum President, Director & Head-Research & Development
Daniel R. Faga Executive VP, Chief Operating & Financial Officer
Faheem Hasnain Chairman
James G. Christensen Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
MIRATI THERAPEUTICS, INC.-18.83%9 203
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156